Ignite Creation Date:
2025-12-24 @ 5:10 PM
Ignite Modification Date:
2026-02-25 @ 5:45 PM
Study NCT ID:
NCT02989350
Status:
COMPLETED
Last Update Posted:
2019-01-30
First Post:
2016-12-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 100}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-01-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-01', 'completionDateStruct': {'date': '2018-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-01-28', 'studyFirstSubmitDate': '2016-12-01', 'studyFirstSubmitQcDate': '2016-12-09', 'lastUpdatePostDateStruct': {'date': '2019-01-30', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-12-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2018-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Duration of diarrhea', 'timeFrame': '8 days', 'description': '(measured in hours) - time until the normalisation of stool consistency according to the Bristol Stool Form Scale(BSF) or Amsterdam Infant Stool Scale (ASF) - (in BSF scale, numbers 1, 2, 3, 4 and 5; in ASF scale, letters B or C), or the time until the normalisation of the number of stools (compared with the period before the onset of diarrhoea).and the presence of normal stools for 48 h.'}], 'secondaryOutcomes': [{'measure': 'Need for intravenous rehydration', 'timeFrame': '8 days', 'description': 'Number of patients in each group requiring intravenous rehydration'}, {'measure': 'Duration of intravenous rehydration', 'timeFrame': '8 days'}, {'measure': 'Need for hospitalisation of outpatients', 'timeFrame': '8 days', 'description': 'Number of patients enrolled as outpatient requiring hospitalisation - based on medical assesment'}, {'measure': 'Number of watery stools per day', 'timeFrame': '8 days'}, {'measure': 'Vomiting', 'timeFrame': '8 days', 'description': 'Number of participants with vomits and number of vomits per day'}, {'measure': 'Recurrence of diarrhoea (in 48 hours after intervention)', 'timeFrame': '48 hours', 'description': 'Number of patients in which diarrhoea recur after initial recovery in 48 hours'}, {'measure': 'Severity of diarrhoea according to Vesikari scale', 'timeFrame': '8 days'}, {'measure': 'Use of concomitant medications', 'timeFrame': '8 days'}, {'measure': 'Adverse events', 'timeFrame': '8 days'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Acute Gastroenteritis']}, 'referencesModule': {'references': [{'pmid': '28835355', 'type': 'DERIVED', 'citation': 'Szymanski H, Szajewska H. Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children: Protocol of a Randomized Controlled Trial. JMIR Res Protoc. 2017 Aug 23;6(8):e164. doi: 10.2196/resprot.7924.'}], 'seeAlsoLinks': [{'url': 'http://www.researchprotocols.org/2017/8/e164/', 'label': 'published protocol'}]}, 'descriptionModule': {'briefSummary': 'Acute gastroenteritis (AGE) is one of the most common diseases among children. Oral rehydration therapy is the key treatment. According to the 2014 guidelines developed by the ESPGHAN probiotics may be considered in the management of children with AGE in addition to rehydration therapy. Considering that evidence on L reuteri remains limited, the investigators aim to assess the efficacy of L reuteri DSM 17938 for the treatment of AGE in children. Children vaccinated and not vaccinated against rotavirus will be evaluated separately.\n\nTwo independent reports (rotavirus-vaccinated and non-vaccinated children) are planned.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '60 Months', 'minimumAge': '2 Months', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Acute gastroenteritis (AGE) defined as a change in stool consistency to loose or liquid form (according to the Bristol Stool Form (BSF) scale or in the case of infants, the Amsterdam Stool Form (ASF) scale) and/or an increase in the frequency of evacuations (typically ≥3 in 24 h), lasting for no longer than 5 days.\n2. Age: older than 1 month and younger than 60 months.\n3. A caregiver must provide written informed consent.\n\nExclusion Criteria:\n\n1. Use of antibiotics within two weeks prior to enrolment.\n2. Use of gelatine tannate, diosmectite, probiotics, racecadotril, or zinc (including zinc containing ORS) within a week prior to enrolment (a single dose is allowed).\n3. Breast feeding (\\>50%)\n4. Chronic diarrhoeal gastrointestinal disease (e.g., inflammatory bowel disease, cystic fibrosis, coeliac disease, food allergy)\n5. Immunodeficiency\n6. Malnutrition (weight/height/length under 3rd percentile) (WHO Child Growth Standards will be used)'}, 'identificationModule': {'nctId': 'NCT02989350', 'briefTitle': 'Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children', 'organization': {'class': 'OTHER', 'fullName': 'Szpital im. Św. Jadwigi Śląskiej'}, 'officialTitle': 'Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children: Randomised Controlled Trial', 'orgStudyIdInfo': {'id': '1/2016'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Lactobacillus reuteri DSM 17938', 'description': '2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.', 'interventionNames': ['Dietary Supplement: Lactobacillus reuteri DSM 17938']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo consists of an identical formulation, except active substance.', 'interventionNames': ['Dietary Supplement: Placebo']}], 'interventions': [{'name': 'Lactobacillus reuteri DSM 17938', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Lactobacillus reuteri DSM 17938 vs Placebo', 'armGroupLabels': ['Lactobacillus reuteri DSM 17938']}, {'name': 'Placebo', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Lactobacillus reuteri DSM 17938 vs Placebo', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '55-100', 'city': 'Trzebnica', 'country': 'Poland', 'facility': 'Szpiatal im.Świętej Jadwigi Śląskiej', 'geoPoint': {'lat': 51.31076, 'lon': 17.06331}}], 'overallOfficials': [{'name': 'Henryk Szymański, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Szpital im.Świętej Jadwigi Śląskiej, Trzebnica, Poland'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Szpital im. Św. Jadwigi Śląskiej', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'MD PhD', 'investigatorFullName': 'Henryk Szymański', 'investigatorAffiliation': 'Szpital im. Św. Jadwigi Śląskiej'}}}}